Take a short break from the clinic and try 2 quick questions about the injectable gut hormone analogs.
The ADA recommends GLP-1 agonists as second-line therapy against type 2 diabetes. What makes this class unique in its impact on hyperglycemia?
Glucagon-like peptide-1 receptor agonists represent a novel class of antihyperglycemic agents that have a cardiac-friendly profile.
Incretin-based therapies have been in use for nearly a decade now, as add-on agents to conventional therapy and as initial treatment for some patients. Here, a quick brush-up on GLP-1 agonists and DPP-4 inhibitors.
Incretin drugs, which offer ease of use, very little hypoglycemia, and no weight gain (or even weight loss) seem to be an ideal therapy. But 80% to 90% of patients don’t stay on them. Why not?
Incretin-based T2DM therapy is not a direct cause of pancreatitis or pancreatic cancer asserts the European Medicines Agency.
GLP-1 receptor antagonists suppress post-meal glucose excursions and are compatible with basal insulin; the combination addresses both FPG and PPG.
Bariatric surgery is recommended along with oral therapy to help patients with type 2 diabetes control overweight and obesity.
Sodium-glucose linked transporter 2 inhibitors lower renal threshold for glucose transport, cause glycosuria, improved glycemic control, weight loss.
Combination therapy that addresses both fasting and post-meal glucose elevation is the next big thing in T2DM management.